ERBB2 and breast cancer: Initial in vitro experiments demonstrated antitumor activity in both HER2-overexpressing breast cancer and EGFR-overexpressing epidermal carcinoma cell lines, with neratinib inhibiting downstream signal transduction events and cell cycle regulatory pathway, and reducing cell proliferation62.